Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
Open Access
- 8 February 2021
- journal article
- review article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 24 (2) , 323-334
Abstract
Background: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging. Patients with nmCRPC progress to metastatic disease and are at risk of developing cancer-related symptoms and morbidity, eventually dying of their disease. While patients with nmCRPC are generally asymptomatic from their disease, they are often older and have chronic comorbidities that require long-term concomitant medication. Therefore, careful consideration of the benefit–risk profile of potential treatments is required. Methods: In this review, we will discuss the rationale for early treatment of patients with nmCRPC to delay metastatic progression and prolong survival, as well as the factors influencing this treatment decision. We will focus on oral pharmacotherapy with the second-generation androgen receptor inhibitors, apalutamide, enzalutamide, and darolutamide, and the importance of balancing the clinical benefit they offer with potential adverse events and the consequential impact on quality of life, physical capacity, and cognitive function. Results and conclusions: While the definition of nmCRPC is well established, the advent of next-generation imaging techniques capable of detecting hitherto undetectable oligometastatic disease in patients with nmCRPC has fostered debate on the criteria that inform the management of these patients. However, despite these developments, published consensus statements have maintained that the absence of metastases on conventional imaging suffices to guide such therapeutic decisions. In addition, the prolonged metastasis-free survival and recently reported positive overall survival outcomes of the three second-generation androgen receptor inhibitors have provided further evidence for the early use of these agents in patients with nmCRPC in order to delay metastases and prolong survival. Here, we discuss the benefit–risk profiles of apalutamide, enzalutamide, and darolutamide based on the data available from their pivotal clinical trials in patients with nmCRPC.Keywords
This publication has 54 references indexed in Scilit:
- Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational StudyJournal of Clinical Medicine, 2014
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling TimeJournal of Clinical Oncology, 2013
- Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?Annals of Oncology, 2012
- Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD AnalysisJournal of Cancer Epidemiology, 2012
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal Of Clinical Practice, 2011
- Impact of Biochemical Recurrence in Prostate Cancer Among US VeteransArchives of internal medicine (1960), 2010
- Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)Journal of Urology, 2010
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Androgen Receptor in Prostate CancerEndocrine Reviews, 2004
- Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate CancerJournal of Urology, 2002